190 results on '"Cruz-Correa, Marcia"'
Search Results
2. Tumor Molecular Profiling in Hispanics: Moving Towards Precision Oncology and Health Equity
3. Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries
4. Supplementary Table S2 from Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer
5. Supplementary Figure S1 from Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer
6. Supplementary Appendix from Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer
7. Data from Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer
8. First-in-human study of ABBV-400, a novel c-Met–targeting antibody-drug conjugate, in advanced solid tumors: Results in colorectal cancer.
9. Fine-mapping analysis including over 254,000 East Asian and European descendants identifies 136 putative colorectal cancer susceptibility genes
10. Supplementary Figure S2 from Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma
11. Supplementary Table S2 from Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma
12. Supplementary Methods S2 from Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma
13. Approach to Familial Predisposition to Colorectal Cancer
14. Fine-mapping analysis including over 254 000 East Asian and European descendants identifies 136 putative colorectal cancer susceptibility genes
15. Author Correction: Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries
16. Implementation of Universal Colorectal Cancer Screening for Lynch Syndrome in Hispanics Living in Puerto Rico
17. Tislelizumab plus chemotherapy (chemo) versus placebo plus chemo as first-line treatment for locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: RATIONALE-305 European/North American patient subgroup.
18. Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Health-related quality of life (HRQoL) outcomes in the RATIONALE-305 study.
19. 1526 Nous-209 genetic vaccine encoding shared cancer neoantigens is safe and elicits robust immune response in healthy Lynch syndrome carriers: interim results from Phase 1 cancer interception trial
20. Genetic epidemiology of BRCA1- and BRCA2-associated cancer across Latin America
21. Supplementary Table S5 from Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma
22. Supplementary Figure S2 from Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma
23. Supplementary Methods S1 from Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma
24. Data from Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma
25. Molecular profiling of colorectal cancer in a genetically admixed Hispanic population
26. Molecular and Sociodemographic Colorectal Cancer Disparities in Latinos Living in Puerto Rico
27. Abstract 995: Evaluation of plasma cytokines and chemokines as potential biomarkers for colorectal cancer detection
28. 108 Pilot Project Awardees Productivity Award Metrics at The Alliance Idea-CTR
29. Supplementary Figure 1 from Hypoxia-Inducible Factor-1 Target Genes as Indicators of Tumor Vessel Response to Vascular Endothelial Growth Factor Inhibition
30. Data from Hypoxia-Inducible Factor-1 Target Genes as Indicators of Tumor Vessel Response to Vascular Endothelial Growth Factor Inhibition
31. Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma
32. Abstract P1-06-07: Interrogating the Molecular Profile of Breast Cancer Tumors in Hispanics Living in Puerto Rico (PRH)
33. Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
34. RELATIVITY-106: A phase 1/2 trial of nivolumab (NIVO) + relatlimab (RELA) in combination with bevacizumab (BEV) in first-line (1L) hepatocellular carcinoma (HCC).
35. Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries
36. Abstract A016: Successful design and execution of two gastric cancer chemoprevention trials in Central America and Puerto Rico
37. Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma
38. S1538 Clinicopathologic Characterization and Genotype Correlation of Duodenal Polyposis Among Hispanics With Familial Adenomatous Polyposis
39. Racial/ethnic disparities in gastric cancer: A 15‐year population‐based analysis
40. Abstract 1172: Interrogating the molecular profile of breast cancer tumors in US Hispanics
41. Abstract CT246: Phase 1b/2 study of giloralimab in combination with modified FOLFIRINOX with or without budigalimab in patients with untreated metastatic pancreatic cancer
42. Abstract 2266: Host genetic susceptibility to COVID-19 and pandemic -associated stressors
43. Abstract 2183: Interrogating the molecular profile of colorectal cancer: detection of clinically actionable alterations in Hispanics
44. Abstract 3526: Host genetic susceptibility to gut microbiota-driven colorectal carcinogenesis
45. Tumor Molecular Profiling in Hispanics: Moving Towards Precision Oncology and Health Equity
46. Phase II trial of weekly erlotinib dosing to reduce duodenal polyp burden associated with familial adenomatous polyposis
47. 1145 EVALUATION OF THE SAFETY AND EFFICACY OF EFLORNITHINE (DIFLUOROMETHYLORNITHINE, DFMO) IN PATIENTS WITH GASTRIC PREMALIGNANT CONDITIONS IN THE HIGH INCIDENCE AREAS OF LATIN AMERICA
48. Racial/ethnic disparities in gastric cancer: A 15‐year population‐based analysis.
49. Polyposis syndromes
50. S1331 Phase II Trial of Weekly Erlotinib Dosing to Reduce Duodenal Polyp Burden Associated With Familial Adenomatous Polyposis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.